<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324077</url>
  </required_header>
  <id_info>
    <org_study_id>CA180-011</org_study_id>
    <nct_id>NCT00324077</nct_id>
  </id_info>
  <brief_title>Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase</brief_title>
  <official_title>A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is
      safe, and whether the combination of the two drugs will help decrease the number of cells
      that contain the Philadelphia chromosome.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient Enrollment
  </why_stopped>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and recommended dose of dasatinib when combined with imatinib in chronic phase CML patients.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess safety and tolerability of dasatinib and imatinib administered in combination throughout study</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identify dose limiting toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize plasma pharmacokinetics of dasatinib and imatinib in month 1</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure major molecular response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure the major cytogenetic response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize mutations in the BCR-ABL gene</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate progressive free survival and overall survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Myeloid Leukemia, Chronic, Chronic-Phase</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib in combination with imatinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females, 18 or older

          -  chronic phase Ph+ or BCR-ABL positive CML

          -  current complete hematologic response to imatinib

          -  lack of major molecular response

          -  on imatinib for at least one year

          -  on the same imatinib dose for at least 6 months

          -  adequate hepatic and renal function

        Exclusion Criteria:

          -  History of accelerated or blast phase CML

          -  Serious uncontrolled medical disorder or active infection

          -  Significant cardiovascular disease or bleeding disorder

          -  Concurrent use of medications at risk of causing Torsades de Pointe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <keyword>Chronic phase chronic myelogenous leukemia (CML)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

